A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
Michael H. Cullen, Petr Zatloukal, S Sörenson et al. · Annals of Oncology · 2008
Cited by 73 works. doi:10.1093/annonc/mdm592
Authors
- Michael H. Cullen
- Petr Zatloukal
- S Sörenson
- Silvia Novello
- J.R. Fischer
- Anil Abraham Joy
- Manuela Zereu
- Patrick M. Peterson
- Carla Visseren‐Grul
- Neil A. Iscoe
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- Regression Models and Life-Tables
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Prediction of Creatinine Clearance from Serum Creatinine
- Categorical Data Analysis
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy